- Global Pharma News & Resources

Kaskela Law LLC Announces Stockholder Investigation of Akcea Therapeutics, Inc. (AKCA) and Encourages Investors to Contact the Firm

PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Akcea Therapeutics, Inc. ("Akcea") (NASDAQ: AKCA) on behalf of the company's shareholders. 

On August 31, 2020, Akcea announced that it had entered into an agreement to be acquired by Ionis Pharmaceuticals, Inc. ("Ionis") for $18.15 per share in cash.

The firm's investigation seeks to determine whether Akcea's directors breached their fiduciary duties in agreeing to sell the company to Ionis, and whether the proposed transaction as structured undervalues Akcea's common stock.

Akcea shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585, or by email at or online at, for additional information about this investigation and their legal rights and options.

Kaskela Law LLC represents investors in securities fraud, corporate governance, and merger & acquisition litigation.  For additional information about Kaskela Law LLC please visit


D. Seamus Kaskela, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 258 – 1585
(888) 715 – 1740

This notice may constitute attorney advertising in certain jurisdictions.

View original content:

SOURCE Kaskela Law LLC

Editor Details

Last Updated: 05-Sep-2020